ArticleCureus2025
Clinical Value of 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) in Radioiodine-Refractory Thyroid Carcinoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioiodine-refractory differentiated thyroid cancer is a condition that arises in patients who develop resistance to the mainstay treatment for thyroid cancer. Although it is relatively uncommon, its clinical significance lies in the fact that it markedly worsens prognosis and calls for the implementation of alternative management strategies for affected patients. This is a case of a 40-year-old woman with a 17-year history of differentiated thyroid cancer, refractory to radioiodine (RAI), showing no iodine-131 uptake on whole body scan scintigraphy and elevated tumor markers. Through 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging, hypermetabolic foci were identified in the lungs, consistent with metastatic recurrent disease. Due to its effectiveness, 18F-FDG PET/CT should be considered for evaluation in cases of clinical suspicion in patients with elevated tumor markers and low iodine-131 uptake, consistent with radioiodine-refractory disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.